Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies

Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies

Runzhe Chen, Fei Wang, Hongming Zhang, Baoan ChenDepartment of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People’s Republic of ChinaBackground: Recently, brentuximab vedotin has b...

Full description

Bibliographic Details
Main Authors: Chen R, Wang F, Zhang H, Chen B
Format: Article
Language:English
Published: Dove Medical Press 2015-04-01
Series:Drug Design, Development and Therapy
Online Access:http://www.dovepress.com/brentuximab-vedotin-for-treatment-of-relapsed-or-refractory-malignant--peer-reviewed-article-DDDT

Internet

http://www.dovepress.com/brentuximab-vedotin-for-treatment-of-relapsed-or-refractory-malignant--peer-reviewed-article-DDDT

Similar Items